*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Aptamer Group operates within the life sciences sector and is a leader in the provision of aptamer discovery and selection services and in developing aptamer-based reagents. The Company operates across three life science sectors: custom services (research and bioprocessing tools), diagnostics and therapeutics. The Company strives to deliver transformational solutions that meet the needs of developers and users of diagnostic platforms, scientific researchers and companies involved in drug development and manufacturing.
Registrars:
Key Personnel
CEO:
Arron Tolley
CFO:
Andrew Rapson
Non-Executive Director:
Timothy J Sykes
Non-Executive Chairman:
Adam Hargreaves
Chief Technical Officer:
David Harry John Bunka
Contact Details
Address:
Windmill House, Innovation Way, Heslington, York, United Kingdom